HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through years in the business of blood collection, processing and storage. In addition we have established a robust donor recruitment and management system which supports an extensive registry of well characterized repeat donors. HemaCare s controlled procedures ensure a readily available inventory of high quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes phenotypic or disease state, for example , or sub sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies.
Quote | Hemacare Corp (OTCMKTS:HEMA)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $25.31 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/07/2020 08:58:12 am |
News | Hemacare Corp (OTCMKTS:HEMA)
Aimed at expanded its footprint in cell therapies, Charles River Laboratories (NYSE: CRL ) has agreed to acquire human-derived cellular products maker HemaCare ( OTCPK:HEMA ) for ~$380M in cash ($25.40 per share). More news on: Charles River Laboratories International, Inc., HemaCare Cor...
– Expands Charles River’s Scientific Capabilities in the High-Growth Cell Therapy Market – – Establishes a Comprehensive Cell Therapy Solution from Discovery through Commercialization – Charles River Laboratories International, Inc. (NYSE: CR...
Message Board Posts | Hemacare Corp (OTCMKTS:HEMA)
Subject | By | Source | When |
---|---|---|---|
$HEMA: Acquired by Charles River Laboratories International, Inc. | Renee | investorshub | 01/03/2020 9:54:09 PM |
So, after all your questions that I told | dg33 | investorshub | 12/16/2019 9:30:06 PM |
whytestocks: $HEMA News Article - HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of H | whytestocks | investorshangout | 12/16/2019 6:40:44 PM |
whytestocks: $HEMA News Article - Charles River Laboratories to Acquire HemaCare Corporation | whytestocks | investorshangout | 12/16/2019 2:05:43 PM |
Can you point to where it is false? | Steve07 | investorshub | 09/23/2019 8:30:57 PM |
News, Short Squeeze, Breakout and More Instantly...
– Expands Charles River’s Scientific Capabilities in the High-Growth Cell Therapy Market – – Establishes a Comprehensive Cell Therapy Solution from Discovery through Commercialization – Charles River Laboratories International, Inc. (NYSE: CR...
Advancing cell and gene therapies with the highest quality GMP-compliant bone marrow starting material HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery,...
New distribution partnership allows high-quality human primary cells to reach the Chinese market HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and c...